Skip to content
Biotechnology, Business Company News

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

HaemaLogiX 2 mins read

Sydney, Australia, 14 November 2023 – HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.


Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Chair.


“I’m immensely proud to have served as HaemaLogiX’s CEO for the past 8 years, during which time we have focused the strategic direction of the company on development of our portfolio from a single immunotherapy asset to potentially seven products, with two now in clinical stages,” Mr Carmine said. “I congratulate Damian on his appointment, and I look forward to working together to further build toward the successful commercialisation of the company and our products.” 


With more than 25 years’ experience in drug commercialisation and portfolio strategy in the pharmaceutical and biotechnology sectors, Mr Clarke-Bruce brings deep clinical knowledge across several therapeutic areas pertinent to HaemaLogiX’s clinical strategy, including oncology, immunology and neuroscience. He also brings an extensive international clinical and pharmaceutical network, which will be invaluable to HaemaLogiX’s commercialisation pathways.


Mr Clarke-Bruce most recently held the position of Managing Director and CEO for Race Oncology. Previous positions include US Executive Director of Marketing in Rare Disease and Head of the Global Launch Leadership Team for Pharming Healthcare Inc., where he was recognised with the CEO award for his role in commercialising leniolosib (Joenja). Mr Clarke-Bruce also held local, global and US-based executive director and leadership roles in therapeutics marketing and sales with Novartis, Celegene and Biogen in immunology and neuroscience.


Mr Clarke-Bruce holds MSci and BSSci degrees (USyd & UNSW) and post graduate qualifications in business management (MGSM) and finance from Harvard University, and in bespoke areas of clinical interest from Harvard University and MIT. He is also a Graduate of the Australia Corporate Institute of Directors (GAICD) and holds a board position with Adnovate Clinical, a UK based global clinical services company.


HaemaLogiX Director Alan Liddle said: “It’s a pleasure to welcome Damian to the HaemaLogiX leadership team. Damian’s extensive knowledge of global strategic commercialisation, along with his experience in business development and licensing, launch excellence and marketing will be instrumental to the next stage of the HaemaLogiX journey. He brings all the knowledge, skills, and capabilities at this pivotal time to guide the clinical development of our lead assets, KappaMab and KMA.CAR-T as we continue ongoing efforts to expand our investor base and secure the necessary funding to invest in our key assets.


“On behalf of the Board, I sincerely thank Bryce for his 8-year tenure as CEO, in which he successfully spearheaded the company’s strategic focus during a period of great global uncertainty. He will be invaluable in his continued role on the Board.”

About us:

About HaemaLogiX Ltd -

Formed in 2014, HaemaLogiX is a public unlisted biotech company researching antibody therapies for multiple myeloma. Multiple myeloma is a haematological (blood) cancer of plasma cells (B cells) that can cause focused damage to a patient's bone marrow. Multiple myeloma is considered treatable but generally incurable. The HaemaLogiX team has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing and commercialisation. The Scientific Advisory Board (SAB) members are internationally recognised experts in monoclonal antibody therapies and haematology. Our current research and clinical trial partners are global leaders in Multiple Myeloma and AL Amyloidosis therapy. HaemaLogiX is located in Sydney, Australia.

Contact details:

Jack McLintock, Corporate Media Relations Manager

IR Department

+61 450 608 022



More from this category

  • Biotechnology
  • 01/12/2023
  • 23:07
HanchorBio Inc.

HanchorBio to Present at the ESMO Immuno-Oncology 2023 Annual Congress

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023. Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.Title:…

  • Agriculture Farming Rural, Business Company News
  • 01/12/2023
  • 16:29

SunRice wins Australian Export Award

MEDIA RELEASE 1 December 2023 SunRice takes home Gold at the Australian Export Awards The SunRice Group is thrilled to have been awarded the Agribusiness, Food and Beverages Award at the 61st Australian Export Awards. Held at Parliament House, the Award is in recognition of outstanding international success in the field of agricultural products, including manufactured foods and beverages. • The SunRice Group is one of Australia’s most iconic food brands and Australia’s number one rice brand. The business started over 70 years ago when a group of Riverina rice growers pooled their resources to build a single rice mill…

  • Contains:
  • Business Company News
  • 30/11/2023
  • 15:24
Chartered Accountants ANZ

CA ANZ Media Release – Superannuation changes pose risk to future generations

30 November 2023 CHARTERED ACCOUNTANTS: TODAY’S PROPOSED SUPERANNUATION CHANGES POSE RISK TO FUTURE GENERATIONS The peak accounting body, Chartered Accountants ANZ (CA ANZ), is raising significant concerns about superannuation changes introduced in the Australian Parliament today. Currently, earnings on money invested in superannuation are taxed at 15 per cent, while under changes proposed today this would double to 30 per cent for balances over $3 million. The ‘changing of the goalposts’ would right now double the tax payable on superannuation for around 80,000 Australians who have followed the rules at all times. And because they are not indexed, they set…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.